Cardinal Health stock edges higher as investors eye FY 2027 guidance

Cardinal Health stock is trading near recent highs as investors focus on the company’s fiscal 2027 earnings guidance and solid analyst consensus expectations.

Cardinal Health stock (ISIN US14149Y1082) is trading close to its recent high, with the latest quote of 234.62 USD at the close on September 1, 2026, according to market data compiled by Yahoo Finance. Cardinal Health, a major US healthcare distributor, remains in focus as investors weigh its fiscal 2027 earnings guidance and the current analyst consensus on profits.

Guidance and analyst expectations set the tone

According to data reported by MarketBeat on September 1, 2026, Cardinal Health has issued fiscal 2027 guidance for earnings per share in a range of 12.40 to 12.60 USD. For the current fiscal year, analysts surveyed in the same overview expect Cardinal Health to post 12.55 USD earnings per share, effectively in line with the midpoint of the company’s own guidance. In the same report, the stock is described as carrying a consensus rating of Moderate Buy, with a consensus target price of 266.56 USD, underscoring that analysts still see upside from the present share price level.

The relationship between the current price of 234.62 USD as of September 1, 2026 and the consensus target of 266.56 USD implies a potential gap of about 31.94 USD per share. That corresponds to an upside of around 13.6 percent if the consensus target is reached, a margin that helps explain the supportive stance of many analysts toward Cardinal Health stock. For investors, the key question in the coming quarters will be whether reported earnings can consistently land within or above the guided range and thereby justify the valuation.

Stock performance and market backdrop

A quote overview from Yahoo Finance shows Cardinal Health stock at 234.62 USD at the close on September 1, 2026, essentially flat on the day with a change of 0.07 USD or 0.03 percent. The previous close is indicated at 234.55 USD, highlighting that the share price has been moving in a narrow range on this trading day. In the same market context, broader US equity indices have shown mixed performance, with reports such as a Las Vegas Sun market summary noting that the S and P 500 fell 0.7 percent on September 1, 2026, signaling a slightly weaker overall environment.

Additional data referenced in a Morningstar quote overview lists Cardinal Health with a recent price of 234.55 USD and an indicative market capitalization around 55,000,000,000 USD as of late August 2026. This valuation level positions Cardinal Health firmly among the larger healthcare and distribution players in the United States. For retail investors, the combination of a sizeable market capitalization and a Moderate Buy consensus tends to signal that the market views the company as an established, relatively liquid equity rather than a high-risk small cap.

The proximity of the current price to recent highs is particularly relevant when measured against analyst expectations. With the share price of 234.62 USD as of September 1, 2026 trading below the 266.56 USD consensus target, Cardinal Health stock has not yet reached the levels implied by the prevailing analyst scenarios. This spread between price and target is one of the main numerical anchors for investors evaluating risk and reward in the coming fiscal periods.

Cardinal Health’s role in healthcare distribution

Cardinal Health plays a central role in healthcare distribution in the United States, supplying pharmaceuticals and medical products to hospitals, pharmacies and other care providers. The company’s earnings guidance for fiscal 2027 in the range of 12.40 to 12.60 USD per share underscores management’s expectation of continued cash flow from its core distribution businesses. In practice, this business model means that Cardinal Health’s profitability is closely linked to volume trends in prescription drugs and medical supplies, as well as to the efficiency of its logistics and inventory management.

For investors, one of the key metrics in this context is earnings per share, which condenses overall performance into a single number that can be compared with peers in the healthcare and distribution sectors. The current consensus expectation of 12.55 USD earnings per share for the ongoing fiscal year, as cited by MarketBeat on September 1, 2026, effectively aligns with the midpoint of the 12.40 to 12.60 USD guided range for fiscal 2027. This alignment suggests that the analyst community broadly accepts management’s earnings trajectory and does not expect dramatic deviations in the near term.

Stock valuation and investor perspective

From a valuation perspective, the gap between the current price of 234.62 USD as of September 1, 2026 and the consensus target of 266.56 USD reflects expectations of earnings growth and operational stability. Assuming the consensus earnings expectation of 12.55 USD for the current fiscal year materializes, Cardinal Health’s price level implies a forward price and earnings ratio in the high teens, a range that many investors consider typical for established healthcare distributors with moderate growth prospects.

The indicative market capitalization of about 55,000,000,000 USD, drawn from Morningstar data for late August 2026, further emphasizes the scale at which Cardinal Health operates. Large capitalization can offer advantages, such as better access to capital markets and an ability to invest in technology and logistics. At the same time, it often means that dramatic percentage moves in the share price are less frequent than in smaller, more volatile names, even when earnings surprises occur.

For shareholders, the central numerical story at this point is therefore the combination of guided earnings in the 12.40 to 12.60 USD range, consensus expectations at 12.55 USD, and a price of 234.62 USD that still sits materially below the 266.56 USD target. How this triangle of figures evolves through the next earnings releases will determine whether Cardinal Health stock can close the roughly 13.6 percent distance to the consensus target or whether expectations must be recalibrated.

Representative product segment

One representative pillar of Cardinal Health’s business is the distribution of branded and generic prescription pharmaceuticals to retail pharmacies and hospital systems throughout the United States. This segment is a major contributor to revenue and earnings, even if the exact revenue split has not been detailed in the same day’s sources. For retail investors, the significance of this pharmaceutical distribution activity lies in its relative resilience: demand for essential medicines tends to be less cyclical than other forms of consumer spending, providing a stabilizing backdrop for the earnings guidance figures that investors are currently watching.

Price level and market data

As of the close on September 1, 2026, Cardinal Health stock trades at 234.62 USD on the New York Stock Exchange, based on the latest quote from Yahoo Finance. The intraday change of 0.07 USD or 0.03 percent versus the previous close of 234.55 USD illustrates that the stock has experienced a calm trading session despite the broader market’s mild decline. The indicative market capitalization of around 55,000,000,000 USD as of late August 2026 gives a sense of the company’s weight in the healthcare distribution sector and the attention it receives from institutional investors.

Cardinal Health stock at a glance

• Company: Cardinal Health Inc.
• ISIN: US14149Y1082
• Ticker: CAH
• Trading venue: NYSE
• Price (as of September 1, 2026): 234.62 USD
• Market capitalization: 55,000,000,000 USD (as of August 29, 2026)
• Sector / Industry: Healthcare distribution and services
• Index membership: S and P 500